Earnings Per Share (EPS) (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of computation of basic and diluted net loss per share attributable to common stockholders

The following table sets forth the computation of basic earnings per share attributable to common stockholders and the participating securities for the periods presented (in thousands, except share and per share data):

Basic EPS:

	July 31, 2024 to December 31, 2024 (Successor)
(amounts in thousands, except share and per share data)	Common Shares		Convertible Securities Notes		Sponsor Earnout
Numerator:
Net loss allocated to each class of participating securities	$	(49,888)	$	—	$	(3,875)
Denominator:
Weighted-average shares outstanding		14,772,692		—		—
Shares issuable to Convertible Securities Notes		—		—		—
Sponsor Earnout		—		—		1,147,500
Net loss per share attributable to each class of participating securities – Basic	$	(3.38)	$	—	$	(3.38)

The following table sets forth the computation of diluted earnings per share attributable to common stockholders for the periods presented (in thousands, except share and per share data):

Diluted EPS:

	Successor
(amounts in thousands, except share and per share data)	July 31, 2024 to December 31, 2024
Numerator:
Net loss – Basic	$	(53,763)
Less: Adjustment for fair value changes to convertible securities notes		(929)
Net loss attributable to common stockholders – Diluted	$	(54,692)
Denominator:
Weighted-average shares outstanding – Basic		14,772,692
Weighted-average effect of shares issuable to Convertible Securities Notes (if-converted method)		—
Weighted-average shares outstanding – Diluted		14,772,692
Net loss per share attributable to common shares – Diluted (if-converted method)	$	(3.70)

Schedule of potentially dilutive securities were excluded from the computation of diluted net loss per share

	Successor
	December 31, 2024
Base Warrants	7,528,727
Convert Warrants	1,500,000
Earn-out Shares, subject to vesting conditions	1,147,500
Stock options issued in connection with the Business Combination	7,587
Total potentially dilutive securities	10,183,814

Adagio Medical Inc

Schedule of computation of basic and diluted net loss per share attributable to common stockholders

	Predecessor
	Period from January 1 to July 30, 2024		Year ended December 31, 2023
Numerator:
Net loss attributable to common stockholders	$	(21,278)	$	(36,590)
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders - basic and diluted		815,854		759,814
Net loss per share attributable to common stockholders - basic and diluted	$	(26.08)	$	(48.16)

Schedule of potentially dilutive securities were excluded from the computation of diluted net loss per share

	Predecessor
	As of July 30, 2024	As of December 31, 2023
Convertible preferred stock	4,732,044	4,939,946
Stock options	740,409	747,001
SVB Warrants	—	49,080
Total potentially dilutive securities	5,472,453	5,736,027